Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.
RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.
3 Disclosed Funding Rounds $59,599,999
0 Participating Investments
Emergency Medicine, Health Care, Genetics, Biotechnology, Medical
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Boston,
Massachusetts,
United States,
North America
(US)
Organizations in Boston in Emergency Medicine,
Organizations in Boston in Health Care,
Organizations in Boston in Genetics,
Organizations in Boston in Biotechnology,
Organizations in Boston in Medical,
Organizations in Massachusetts in Emergency Medicine,
Organizations in Massachusetts in Health Care,
Organizations in Massachusetts in Genetics,
Organizations in Massachusetts in Biotechnology,
Organizations in Massachusetts in Medical,
Organizations in United States in Emergency Medicine,
Organizations in United States in Health Care,
Organizations in United States in Genetics,
Organizations in United States in Biotechnology,
Organizations in United States in Medical,
Organizations in North America in Emergency Medicine,
Organizations in North America in Health Care,
Organizations in North America in Genetics,
Organizations in North America in Biotechnology,
Organizations in North America in Medical
Investors in Boston in Emergency Medicine,
Investors in Boston in Health Care,
Investors in Boston in Genetics,
Investors in Boston in Biotechnology,
Investors in Boston in Medical,
Investors in Massachusetts in Emergency Medicine,
Investors in Massachusetts in Health Care,
Investors in Massachusetts in Genetics,
Investors in Massachusetts in Biotechnology,
Investors in Massachusetts in Medical,
Investors in United States in Emergency Medicine,
Investors in United States in Health Care,
Investors in United States in Genetics,
Investors in United States in Biotechnology,
Investors in United States in Medical,
Investors in North America in Emergency Medicine,
Investors in North America in Health Care,
Investors in North America in Genetics,
Investors in North America in Biotechnology,
Investors in North America in Medical
Greater Boston Area (0 Investors) (0 Startups), New England (0 Investors) (0 Startups), East Coast (0 Investors) (0 Startups), Northeastern US (0 Investors) (0 Startups)
Founded date 01, 2016
Operating Status Active
Funding Stage Early Stage Venture
Last Funding Type Series A
Also known as Entrada
Company Type For Profit
Contact
Hunter Lookup
LinkedIN
Wikipedia
Entrada Therapeutics’ mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada’s technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes. The Company's novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the delivery of molecules into the cytosol. For more information, please visit www.entradatx.com.
| Date | Round | Raised | Lead |
|---|---|---|---|
| March, 31, 2021 | Series B | $116,000,000 |
Wellington Management
|
| December, 18, 2018 | Series A | $59,000,000 |
MPM Capital,
5AM Ventures
|
| October, 27, 2016 | Seed | $599,999 | ------- |
| Investor | Lead? | Round | Participating Raise | Date | Partners | ||
|---|---|---|---|---|---|---|---|
|
TCG Crossover | No | Series B | $116,000,000 | March, 31, 2021 | ------- | |
|
|
|
Wellington Management | Yes | Series B | $116,000,000 | March, 31, 2021 | ------- |
|
|
Roche Venture Fund | No | Series B | $116,000,000 | March, 31, 2021 | ------- |
|
|
|
Redmile Group | No | Series B | $116,000,000 | March, 31, 2021 | ------- |
|
|
Qatar Investment Authority | No | Series B | $116,000,000 | March, 31, 2021 | ------- |
|
|
|
Point72 Ventures | No | Series B | $116,000,000 | March, 31, 2021 | ------- |
|
|
|
MRL Ventures Fund | No | Series B | $116,000,000 | March, 31, 2021 | ------- |
|
|
|
MPM Capital | No | Series B | $116,000,000 | March, 31, 2021 | ------- |
|
|
Moore Strategic Ventures | No | Series B | $116,000,000 | March, 31, 2021 | ------- | |
|
|
|
Greenspring Associates | No | Series B | $116,000,000 | March, 31, 2021 | ------- |
|
|
|
Goldman Sachs | No | Series B | $116,000,000 | March, 31, 2021 | ------- |
|
|
|
Agent Capital | No | Series B | $116,000,000 | March, 31, 2021 | ------- |
|
|
|
5AM Ventures | No | Series B | $116,000,000 | March, 31, 2021 | ------- |
|
|
|
CureDuchenne Ventures | No | Series B | $116,000,000 | March, 31, 2021 | ------- |
|
|
|
Agent Capital | No | Series A | $59,000,000 | December, 18, 2018 | ------- |
|
|
|
Roche Venture Fund | No | Series A | $59,000,000 | December, 18, 2018 | ------- |
|
|
|
MRL Ventures Fund | No | Series A | $59,000,000 | December, 18, 2018 | ------- |
|
|
|
MPM Capital | Yes | Series A | $59,000,000 | December, 18, 2018 | ------- |
|
|
|
5AM Ventures | Yes | Series A | $59,000,000 | December, 18, 2018 | ------- |
Betakit
